FAAH inhibitors in the limelight, but regrettably
Résumé
This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events. 3 See refs. on Clinicaltrials.gov: NCT02134080,
Origine | Publication financée par une institution |
---|---|
Licence |